Thyroid Ablation Devices Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product (Non-Thermal Based Devices and Thermal-Based Devices), By Application (Thyroid Nodules, and Thyroid Cancer), By End User (Hospitals & Clinics, Ambulatory Surgical Centers, Others), By Region and Competition, 2021-2031F

Key Insights	Details
Forecast Period	2027-2031
Market Size (2025)	USD 163.89 Million
CAGR (2026-2031)	7.45%
Fastest Growing Segment	Non-Thermal Based Devices
Largest Market	North America
Market Size (2031)	USD 252.23 Million

Market Overview

The Global Thyroid Ablation Devices Market is projected to grow from USD 163.89 Million in 2025 to USD 252.23 Million by 2031 at a 7.45% CAGR. Thyroid ablation devices are medical instruments specifically engineered for the minimally invasive treatment of thyroid nodules and select thyroid cancers, utilizing energy modalities such as radiofrequency or microwave to precisely destroy abnormal thyroid tissue. The market for these devices is propelled by the escalating global incidence of thyroid disorders and a growing patient preference for less invasive therapeutic interventions offering faster recovery. According to the American Cancer Society, an estimated 45,240 new cases of thyroid cancer are projected in the United States for 2026, indicating a significant target population for these advanced treatments.

However, a notable challenge restraining market expansion is the substantial cost associated with these sophisticated devices. This can limit their widespread adoption, particularly within cost-sensitive healthcare systems and emerging economies, thereby impeding broader market penetration and patient access.

Key Market Drivers

Rising disease burden driving demand for thyroid ablation devices
Rising global incidence of thyroid cancer and thyroid nodules significantly drives the demand for thyroid ablation devices. Early detection and improved diagnostic capabilities contribute to identifying a larger patient pool requiring treatment. According to a study published in September 2025, in "Global burden of thyroid cancer attributed to high body mass index and predictive trends", global new cases of thyroid cancer were projected to reach 821,000 in 2022. This expanding prevalence necessitates effective and less invasive therapeutic options, such as ablation technologies, for managing both malignant and benign thyroid conditions, thereby fueling market expansion.

Shift toward minimally invasive treatment and demonstrated adoption of ablation technologies
Concurrently, a growing preference for minimally invasive surgical procedures profoundly influences the adoption of thyroid ablation devices. Patients increasingly favor interventions that offer reduced trauma, shorter recovery times, and improved cosmetic outcomes compared to traditional open surgeries. According to the AAO-HNS Bulletin, September 2025, in "The Current State of Radiofrequency Ablation (RFA) in Thyroid Nodules", 40% of patients with papillary thyroid microcarcinoma who initially favored active surveillance over surgery chose radiofrequency ablation when offered. This shift underscores a broader trend towards less invasive treatments across medical specialties. Demonstrating this wider market dynamism, Medtronic's third quarter fiscal year 2026 financial results, released February 17, 2026, indicated its Cardiac Ablation Solutions revenue increased by 80%, reflecting robust growth in ablation technologies relevant to various applications, including thyroid.

Download Free Sample Report

Key Market Challenges

The substantial cost associated with thyroid ablation devices directly hampers the growth of the global market. This economic barrier limits the widespread adoption of these advanced medical instruments, particularly within healthcare systems that operate under strict budgetary constraints and in developing economies where resource allocation is critical. Such high initial investment costs for equipment can deter procurement by hospitals and clinics, restricting market penetration and patient access to these minimally invasive treatments.

Healthcare providers face mounting financial pressures, which in turn impacts their capacity to invest in costly new technologies. According to the American Hospital Association, in 2025, hospitals and health systems faced increasing financial pressure due to rising labor costs and inflation outpacing reimbursements. Additionally, the Centers for Medicare & Medicaid Services (CMS) finalized a 2.83% reduction in the 2025 Physician Fee Schedule conversion factor, lowering it from $33.29 to $32.35. This reduction directly affects the reimbursement rates for medical procedures, making it more challenging for facilities to justify the acquisition and utilization of expensive thyroid ablation devices, thus impeding market expansion.

Key Market Trends

The growing utilization of ambulatory surgical centers (ASCs) represents a significant trend influencing the global thyroid ablation devices market, as these facilities offer a cost-effective alternative to traditional hospital settings. This shift is driven by favorable reimbursement policies and the inherent efficiencies of specialized outpatient care, making minimally invasive thyroid ablation procedures more accessible to a broader patient population. The focus on outpatient settings supports quicker patient turnover and potentially lower procedural costs, which is appealing to both patients and healthcare providers. According to the Ambulatory Surgery Center Association, November 2025, Medicare payments to ASCs are projected to increase by 2.8% in 2026, further incentivizing the expansion of services, including thyroid ablation, within these facilities.

Concurrently, the integration of robotics and artificial intelligence (AI) into ablation procedures is poised to redefine precision and safety in the global market. These advanced technologies aim to enhance procedural accuracy, minimize human variability, and optimize treatment planning, leading to improved patient outcomes for thyroid conditions. Robotic systems can provide greater dexterity and stability during complex procedures, while AI algorithms offer sophisticated real-time data analysis for enhanced guidance and post-procedure assessment. For example, a surgical intelligence company focused on advancing AI and machine learning in surgery, Activ Surgical, raised $15 million in December 2025 in an oversubscribed Series A funding round to further develop its platform.

Segmental Insights

The Non-Thermal Based Devices segment is experiencing rapid growth in the Global Thyroid Ablation Devices Market due to its distinct advantages. These devices precisely target and destroy only specific cells, critically preserving the functional integrity of surrounding extracellular structures. This capability allows for the safe ablation of thyroid tissues located near sensitive areas such as major blood vessels, the esophagus, and nerves, which is a significant clinical benefit. Consequently, patient preference for less invasive procedures with reduced collateral damage and enhanced safety drives the accelerated adoption of these innovative technologies in treating thyroid conditions.

Regional Insights

North America stands as the leading region in the Global Thyroid Ablation Devices Market, demonstrating significant market share. This dominance is attributed to a high prevalence of thyroid disorders, including thyroid cancer and nodules, across the region. Furthermore, North America benefits from a well-established and advanced healthcare infrastructure, facilitating the widespread adoption of minimally invasive thyroid ablation procedures. The presence of key market players, substantial investments in research and development, and supportive healthcare coverage policies, along with regulatory oversight from bodies like the U.S. Food and Drug Administration and Health Canada, collectively contribute to its prominent market position.

Recent Developments

• In February 2026, Baird Medical, a prominent company in minimally invasive Microwave Ablation (MWA) technology, announced the strategic commercial deployment of its MWA system at Bakersfield Memorial Hospital in California. This event marked the successful completion of the first benign thyroid tumor ablation in central California using Baird Medical's technology, establishing a key regional clinical milestone. The commercial launch further advanced Baird Medical's U.S. expansion strategy, extending its presence within the San Joaquin Valley and aiming to improve patient access to advanced interventional therapies in high-volume medical centers. This initiative signifies a notable development in the global thyroid ablation devices market.
• In December 2025, Pulse Biosciences Inc. announced a significant research collaboration with The University of Texas MD Anderson Cancer Center. This partnership aimed to investigate the company's novel Nanosecond Pulsed Field Ablation (nsPFA) technology for treating thyroid cancers. The U.S. Food and Drug Administration (FDA) granted an Investigational Device Exemption for a first-in-human clinical feasibility study. This study, scheduled to begin in early 2026, intended to enroll 30 patients across two sites to evaluate the safety and effectiveness of the nPulse Vybrance Percutaneous Electrode System for papillary thyroid microcarcinoma. This initiative represents breakthrough research in the global thyroid ablation devices market.
• In October 2025, COMPAL's medical business unit, alongside its subsidiaries, introduced the AblatePal™ RF Ablation System at the 11th Asian Conference on Tumor Ablation (ACTA 2025). The AblatePal™ system was presented as Taiwan's first domestically-developed advanced radio-frequency ablation solution, designed for treating various tumors, including those in the thyroid, liver, and other soft tissues. This new product launch emphasized the company's integrated innovations in smart healthcare, focusing on precision, safety, and high-performance ablation therapy. The exhibition highlighted COMPAL's dedication to advancing smart healthcare technologies and its capabilities in developing sophisticated medical devices for the global thyroid ablation devices market.
• In September 2025, Baird Medical, a company specializing in minimally invasive Microwave Ablation (MWA) technology, announced its successful participation in the American Thyroid Association (ATA) Annual Meeting. The company showcased its advanced ablation technology, underscoring its commitment to collaborating with the global medical community to enhance the standard of care for thyroid disease. During the event, a presentation featured data from over 200 MWA procedures, highlighting the technology's effectiveness as a treatment alternative, particularly for patients where previous radiofrequency ablation treatments had been unsuccessful. This reinforced Baird Medical's position in the global thyroid ablation devices market.

Key Market Players

• Medtronic Plc
• StarMed Co. Ltd.
• Terumo Corporation
• Johnson & Johnson
• Theraclion SA
• Integra LifeSciences Corporation
• Olympus Corporation
• MedWaves Inc
• BVM Medical System
• Boston Scientific Corporation

By Product	By Application	By End User	By Region
Non-Thermal Based Devices Thermal-Based Devices	Thyroid Nodules Thyroid Cancer	Hospitals & Clinics Ambulatory Surgical Centers Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Thyroid Ablation Devices Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Thyroid Ablation Devices Market, By Product:

• Non-Thermal Based Devices
• Thermal-Based Devices

• Thyroid Ablation Devices Market, By Application:

• Thyroid Nodules
• Thyroid Cancer

• Thyroid Ablation Devices Market, By End User:

• Hospitals & Clinics
• Ambulatory Surgical Centers
• Others

• Thyroid Ablation Devices Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE